ESPE2018 Poster Presentations GH & IGFs P3 (28 abstracts)
Growth Hormone Treatment: Does Timing Matter?
Bernardo Marques a , Sónia Madeira Gomes b , Joana Serra Caetano c , Rita Cardoso c , Isabel Dinis c , Alice Mirante c , Ana Laura Fitas b , Catarina Diamantino b , Catarina Limbert b , Rosa Pina b & Lurdes Lopes b
aInstituto Português de Oncologia de Coimbra FG, EPE, Coimbra, Portugal; bCentro Hospitalar de Lisboa Central, EPE, Lisbon, Portugal; cCentro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal
Introduction: Treatment with recombinant growth hormone (rGH) is safe and has greatly improved the approach of children and adolescents with growth hormone deficiency (GHD) and other growth disorders. Some studies show that most of the height gain associated with GH treatment occurs in prepubertal years. The aim of our study was to evaluate the effect of age at start of the treatment on final height in children with isolated or GHD in a Portuguese cohort.
Methods/design: We performed a retrospective and comparative study of 92 patients who completed treatment with rGH. The parameters evaluated included sex, diagnosis, mid-parental height (MPH), height at the beginning and end of treatment and duration of treatment during pre-puberty/early puberty. Girls with <10 years and boys with <11 years (group 1; n=50 patients) were compared to girls with ≥10 years and boys with ≥11 (group 2, n=42 patients). Statistical analysis was performed using paired and independent t-test samples; results are presented as mean±S.D.
Results: Most patients had isolated GHD (n=66; 72%) and were male (n=60; 65%). Mean age at the start of treatment was 9.8±3.5 years and mean duration of treatment was 6.2±3.9 years (group 1–9.3±3.9 vs group 2–3.69.3±1.4; P<0.001). Patients in group 1 had more pre-pubertal years of treatment (6.2±3.1 vs 0.97±0.4 years; P<0.001). At the start of treatment, mean height standard deviation score (HSDS) was higher in group 1 [−2.7±1.7 SDS versus −2.9±0.8 SDS); P<0.001]. Final HSDS was also greater in group 1 (−1±1.2 SDS vs −1.5±0.7 SDS; P=0.001], as was DHSDS (+2.1±1.7 SDS vs +1.38±0.8 SDS; P=0.015). The majority of patients attained MPH, although there was a non-statistically difference between the two groups (−1.1±9 cm in group 1 vs −5.6±7 cm in group 2). Eighty percent of patients achieved a final height between −2 and +2 S.D.S.
Discussion: Our results show that in this cohort of treated Portuguese children with GHD, younger age at the start of treatment was associated with improved final height and underscores the need for early diagnosis and therapy.
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Abstracts
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more